IFNA1 and autoimmune polyendocrine syndrome type 1: By extension, our data also provide evidence of the efficacy of mRNA vaccines in patients with other inborn errors of type I IFN immunity and in patients with APS-1, whose early-onset neutralizing autoantibodies against IFN-α and -ω are responsible for life-threatening COVID-19 (Bastard et al., 2021b; Beccuti et al., 2020; Hetemäki et al., 2021; Meisel et al., 2021; Zhang et al., 2022).